Pharmacokinetic/Pharmacodynamic (PK/PD) Studies of Methylphenidate Extended Release Products in Attention Deficit Hyperactivity Disorder (ADHD) Patients (U01)

Funding Opportunity Number: RFA-FD-14-015 Opportunity Category: DiscretionaryFunding Instrument Type: Cooperative AgreementCategory of Funding Activity: HealthScience and Technology and other Research and DevelopmentCFDA Number: 93.103Eligible Applicants State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher educationNonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher educationPrivate institutions of higher educationFor profit organizations other than small businessesSmall businessesOthers (see text field entitled "Additional Information on Eligibility" for clarification)Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"Agency Name: HHS-FDAClosing Date: Jun 11, 2014Award Ceiling: $1,000,000Expected Number of Awards: 1Creation Date: Apr 29, 2014Funding Opportunity Description: The purpose of this project is to conduct a prospective PK/PD study in attention deficit hyperactivity disorder (ADHD) patients t...
Source: Grants.gov - Category: Research Tags: Health Science and Technology and other Research and Development Source Type: funding

Related Links:

Publication date: Available online 12 November 2019Source: NeuroImageAuthor(s): Juha Salmi, Mostafa Metwaly, Jussi Tohka, Kimmo Alho, Sami Leppämäki, Pekka Tani, Anniina Koski, Tamara Vanderwal, Matti LaineAbstractIndividuals with attention-deficit/hyperactivity disorder (ADHD) have difficulties navigating dynamic everyday situations that contain multiple sensory inputs that need to either be attended to or ignored. As conventional experimental tasks lack this type of everyday complexity, we administered a film-based multi-talker condition with auditory distractors in the background. ADHD-related aberrant brain r...
Source: NeuroImage - Category: Neuroscience Source Type: research
CONCLUSION: This case report suggests that health and wellness coaching can be effective in supporting beneficial outcomes and can be useful in the multimodal management of ADHD. PMID: 31710834 [PubMed - in process]
Source: The Permanente journal - Category: General Medicine Tags: Perm J Source Type: research
The fate of a local company ’s treatment for attention deficit hyperactivity disorder is now in regulators’ hands. Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) has submitted its application to the Food and Drug Administration to take its ADHD drug to market, the company announced Monday. If granted, that could mean gettin g the treatment to patients in the second half of 2020. Supernus has put the product candidate through a handful of phase 3 clinical trials, to study its ability to reduce ADHD…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Up to 60% of children with Attention-Deficit/Hyperactivity Disorder (ADHD) meet diagnostic criteria for at least one anxiety disorder, including Social, Generalized and/or Separation Disorder. Anxiety in child...
Source: BMC Psychiatry - Category: Psychiatry Authors: Tags: Study protocol Source Type: research
The fate of a local company ’s treatment for attention deficit hyperactivity disorder is now in regulators’ hands. Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) has submitted its application to the Food and Drug Administration to take its ADHD drug to market, the company announced Monday. If granted, that could mean gettin g the treatment to patients in the second half of 2020. Supernus has put the product candidate through a handful of phase 3 clinical trials, to study its ability to reduce ADHD…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Abstract Sluggish cognitive tempo (SCT) appears to be distinct from attention-deficit/hyperactivity disorder (ADHD) and unique patterns of association between SCT and comorbid symptoms have been reported in the literature. The current study examined the relation between environmental supports and comorbid concerns among children with high SCT. Parents of children (ages 6-12) with a diagnosis of ADHD and clinically elevated SCT (N = 126) completed measures of emotional/behavioral functioning, child routines, and parental adjustment. Regression analyses revealed that after controlling for child age and...
Source: Child Psychiatry and Human Development - Category: Child Development Authors: Tags: Child Psychiatry Hum Dev Source Type: research
CONCLUSIONS: Differences in ADHD course - persistence, remission and late-onset - were not directly reflected in changes in IQ. Instead, having ADHD at any point across development was associated with lower average IQ and poorer executive functioning. Our finding that individuals with persistent ADHD have poorer response inhibition than those who remitted requires replication. PMID: 31718730 [PubMed - as supplied by publisher]
Source: Psychological Medicine - Category: Psychiatry Authors: Tags: Psychol Med Source Type: research
Translational Psychiatry, Published online: 13 November 2019; doi:10.1038/s41398-019-0614-3Motor cortex facilitation: a marker of attention deficit hyperactivity disorder co-occurrence in autism spectrum disorder
Source: Translational Psychiatry - Category: Psychiatry Authors: Source Type: research
In conclusion, our meta-analysis showed that there was no statistically significant difference in blood zinc and hair zinc levels between ADHD children and adolescents compared with healthy children and adolescents. PMID: 31704595 [PubMed - as supplied by publisher]
Source: Asian Journal of Psychiatry - Category: Psychiatry Tags: Asian J Psychiatr Source Type: research
Widening definitions of health conditions have the potential to affect millions of people and should only occur when there is strong evidence of benefit. In the last version of the Diagnostic and Statistical M...
Source: BMC Psychiatry - Category: Psychiatry Authors: Tags: Research article Source Type: research
More News: ADHD | Concerta | Funding | Grants | Health | Hyperactivity | Methylphenidate | Research | Ritalin | Science | Study